10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
10x Genomics has launched two new Chromium products to make single cell analysis more accessible and affordable. The GEM-X Flex and GEM-X Universal Multiplex offer improved performance, workflow, and cost-effectiveness. GEM-X Flex enables profiling of up to 2.5 million cells per run at a cost as low as $0.01 per cell, with compatibility for various sample types including FFPE samples. It requires as low as 25,000 cells per sample, a four-fold improvement in sample recovery.
The GEM-X Universal Multiplex allows on-chip multiplexing of four independent samples, up to 5,000 cells per sample, for approximately $560 per sample. This simplifies the workflow and reduces hands-on time. Both products aim to democratize single cell analysis by lowering costs per cell, sample, experiment, and project.
10x Genomics ha lanciato due nuovi prodotti Chromium per rendere l'analisi delle singole cellule più accessibile ed economica. Il GEM-X Flex e il GEM-X Universal Multiplex offrono prestazioni migliorate, flussi di lavoro semplificati e un rapporto costo-efficacia elevato. Il GEM-X Flex consente di profilare fino a 2,5 milioni di cellule per corsa a un costo di solo $0,01 per cellula, con compatibilità per vari tipi di campioni, inclusi i campioni FFPE. Richiede solo 25.000 cellule per campione, un miglioramento di quattro volte nel recupero dei campioni.
Il GEM-X Universal Multiplex consente il multiplexing su chip di quattro campioni indipendenti, fino a 5.000 cellule per campione, per circa $560 per campione. Questo semplifica il flusso di lavoro e riduce i tempi di interazione manuale. Entrambi i prodotti mirano a democratizzare l'analisi delle singole cellule abbattendo i costi per cellula, campione, esperimento e progetto.
10x Genomics ha lanzado dos nuevos productos de Chromium para hacer que el análisis de células individuales sea más accesible y asequible. El GEM-X Flex y el GEM-X Universal Multiplex ofrecen un rendimiento mejorado, un flujo de trabajo optimizado y una relación costo-efectividad. El GEM-X Flex permite el perfilado de hasta 2.5 millones de células por ejecución a un costo tan bajo como $0.01 por célula, con compatibilidad para varios tipos de muestras, incluyendo muestras FFPE. Requiere tan solo 25,000 células por muestra, una mejora de cuatro veces en la recuperación de muestras.
El GEM-X Universal Multiplex permite la multiplexación en chip de cuatro muestras independientes, hasta 5,000 células por muestra, por aproximadamente $560 por muestra. Esto simplifica el flujo de trabajo y reduce el tiempo de manejo. Ambos productos tienen como objetivo democratizar el análisis de células individuales al reducir los costos por célula, muestra, experimento y proyecto.
10x Genomics는 단일 세포 분석을 더 접근 가능하고 저렴하게 만들기 위해 두 가지 새로운 Chromium 제품을 출시했습니다. GEM-X Flex와 GEM-X Universal Multiplex는 향상된 성능, 작업 흐름 및 비용 효과성을 제공합니다. GEM-X Flex는 최대 250만 세포를 한 번에 프로파일링할 수 있으며, 세포당 비용은 단 $0.01로 다양한 샘플 유형(FFPE 샘플 포함)과 호환됩니다. 샘플당 25,000세포만 필요하며, 이는 샘플 회수율에서 네 배의 개선 효과를 보여줍니다.
GEM-X Universal Multiplex는 네 개의 독립 샘플을 칩에서 동시에 처리할 수 있게 해주며, 샘플당 최대 5,000세포를 처리할 수 있습니다. 샘플당 약 $560의 비용이 발생합니다. 이는 작업 흐름을 간소화하고 수작업 시간을 줄여줍니다. 두 제품 모두 세포당, 샘플당, 실험당 및 프로젝트당 비용을 낮추어 단일 세포 분석을 민주화하는 것을 목표로 하고 있습니다.
10x Genomics a lancé deux nouveaux produits Chromium afin de rendre l'analyse des cellules uniques plus accessible et abordable. Le GEM-X Flex et le GEM-X Universal Multiplex offrent de meilleures performances, un flux de travail amélioré et une rentabilité accrue. Le GEM-X Flex permet de profiler jusqu'à 2,5 millions de cellules par course à un coût aussi bas que 0,01 $ par cellule, tout en étant compatible avec divers types d'échantillons, y compris les échantillons FFPE. Il nécessite seulement 25 000 cellules par échantillon, représentant une amélioration quadruple de la récupération des échantillons.
Le GEM-X Universal Multiplex permet le multiplexage de quatre échantillons indépendants sur puce, jusqu'à 5 000 cellules par échantillon, pour environ 560 $ par échantillon. Cela simplifie le flux de travail et réduit le temps d'interaction manuelle. Les deux produits visent à démocratiser l'analyse des cellules uniques en abaissant les coûts par cellule, échantillon, expérience et projet.
10x Genomics hat zwei neue Chromium-Produkte eingeführt, um die Analyse einzelner Zellen zugänglicher und erschwinglicher zu machen. Der GEM-X Flex und der GEM-X Universal Multiplex bieten verbesserte Leistung, optimierte Arbeitsabläufe und Kosteneffektivität. Der GEM-X Flex ermöglicht das Profiling von bis zu 2,5 Millionen Zellen pro Lauf zu einem Preis von nur $0,01 pro Zelle, mit Kompatibilität für verschiedene Probenarten, einschließlich FFPE-Proben. Er benötigt nur 25.000 Zellen pro Probe, was eine vierfache Verbesserung bei der Probenrückgewinnung darstellt.
Der GEM-X Universal Multiplex erlaubt die On-Chip-Multiplexierung von vier unabhängigen Proben, bis zu 5.000 Zellen pro Probe, für etwa $560 pro Probe. Dies vereinfacht den Workflow und reduziert die manuellen Arbeitszeiten. Beide Produkte zielen darauf ab, die Analyse einzelner Zellen zu demokratisieren, indem die Kosten pro Zelle, Probe, Experiment und Projekt gesenkt werden.
- Launch of GEM-X Flex enables profiling up to 2.5 million cells per run at a cost as low as $0.01 per cell
- GEM-X Flex offers improved sample recovery with input recommendations as low as 25,000 cells per sample
- GEM-X Universal Multiplex allows running four independent samples for approximately $560 per sample
- New products aim to lower customer costs and drive widespread adoption of single cell analysis
- None.
Insights
The launch of GEM-X Flex and GEM-X Universal Multiplex represents a significant strategic move for 10x Genomics. By dramatically reducing the cost per cell to
The ability to process FFPE samples and the improved sample recovery (now requiring as few as 25,000 cells) could expand 10x Genomics' addressable market, potentially leading to increased adoption in clinical and translational research settings. The new GEM-X Universal Multiplex, priced at approximately
These innovations align with the company's strategy to democratize single cell analysis, which could lead to increased instrument placements and consumables sales. However, investors should monitor how these lower-priced offerings impact overall profit margins and whether the expected volume increase will offset potential price pressures.
The introduction of GEM-X Flex and GEM-X Universal Multiplex represents a significant advancement in single cell analysis technology. The ability to analyze up to 5 million cells per kit at a cost of
The compatibility with FFPE samples is particularly noteworthy, as it allows researchers to tap into vast archives of clinical samples, potentially accelerating biomarker discovery and drug development processes. The improved sample recovery, now requiring only 25,000 cells, could be game-changing for researchers working with samples like biopsies or rare cell populations.
The on-chip multiplexing capability of GEM-X Universal Multiplex, allowing four samples to be processed simultaneously, addresses a key pain point in single cell workflows. This could significantly increase throughput and reduce hands-on time, making the technology more attractive to high-volume labs and core facilities.
These advancements could accelerate the adoption of single cell analysis across various fields of biology and medicine, potentially leading to breakthroughs in our understanding of complex diseases and cellular processes.
These launches are part of the company's strategy to drive widespread adoption of single cell analysis by lowering customer costs in multiple directions: per cell, per sample, per experiment and per project. With these advances, 10x Genomics is addressing the growing demand for high-throughput single cell applications and providing cost-effective offerings to help new researchers getting started in single cell and existing labs looking to scale up their research.
"These launches are an integral part of our ongoing push to democratize single cell analysis and make it more accessible and more affordable for more researchers than ever before," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "They add to a growing list of new single cell products, protocols and capabilities that make 2024 the most exciting year of Chromium innovation in the platform's history. We can't wait to see how labs of all sizes take advantage of the leading performance, scalability and affordability of our GEM-X portfolio to fuel their research."
GEM-X Flex: Superior performance and ultra low cost per cell
GEM-X Flex Gene Expression brings 10x Genomics' highest performing and most flexible assay – Chromium Flex – to the company's new GEM-X technology architecture, delivering superior performance and substantial cost savings and enabling single cell analysis at mega scale.
Since its initial launch in 2022, Chromium Flex has delivered class-leading performance across a broad range of sample types and became the first and only commercial single cell assay compatible with FFPE samples. Now on the GEM-X architecture, Flex adds the scalability to run millions of cells for less than
Key Performance Specifications:
- Ultimate flexibility for low cost at any scale: Researchers can benefit from the highest sequencing efficiency to reduce total project costs, as well as fix, batch and run samples on their own schedule without compromising on data quality.
- Built for mega scale: With GEM-X Flex, researchers can profile up to 2.5 million cells per run and 5 million cells per kit, for a cost as low as
$0.01 - Unlock previously inaccessible sample types: Flex is the only single cell assay compatible with a wide range of sample types: fresh, frozen, PFA-fixed tissue, whole blood, and FFPE samples.
- Improved sample recovery: With new input recommendations as low as 25,000 cells per sample, GEM-X Flex delivers a four-fold improvement in sample recovery and enables researchers to explore limited samples like small tissue biopsies and flow-sorted cells.
"Chromium Flex has set a new standard in routine sample preservation for our core facility users, offering a flexible and reliable way to preserve biological material for future analysis. We've already sequenced hundreds of samples and likely have a multitude more biobanked in the freezer, ready for future studies," said Niels Vandamme, Head of VIB Single Cell Core (Ghent University and KU Leuven). "The GEM-X Flex workflow is truly the best of both worlds. Researchers can now take advantage of enhanced sample fixation protocols that require lower cell input while benefiting from GEM-X's improved cell capture capabilities. This workflow opens up new possibilities for both small-scale and high-throughput projects."
GEM-X Flex Gene Expression, compatible exclusively with Chromium iX and X instruments, is now shipping to customers globally.
GEM-X Universal Multiplex: Easy on-chip multiplexing delivers significantly lower per sample cost
10x Genomics is also introducing new on-chip multiplexing capabilities for its flagship GEM-X Universal 3' and 5' Gene Expression assays, enabling researchers to run more cost-effective single cell studies even at small scale.
With GEM-X Universal Multiplex, researchers can batch and run four independent samples, up to 5,000 cells per sample, for approximately
Key Performance Specifications:
- Exceptional performance and superior data quality: GEM-X Universal Multiplex delivers performance consistent with the company's flagship GEM-X 3' and 5' Gene Expression kits.
- Significantly lower per sample cost: Perform single cell analysis for approximately
$560 - Broad sample compatibility: Analyze diverse species and sample types incompatible with other multiplexing methods. The GEM-X Universal 3' and 5' assays are also compatible with upstream fixation for flexible sample processing and storage.
- Easy multiplexing workflow: 10x Genomics' unique, on-chip multiplexing workflow eliminates the need for upstream sample tagging and enables high cell recovery with low cell input requirements, ideally suited for limited samples including organoids and stem cells.
"GEM-X Universal Multiplex not only drives large-scale, high-throughput projects, but also lowers barriers for new users," added Vandamme. "Its clean multiplexing strategy enables affordable entry into the field without the complexity of additional labeling requirements, making it ideal for pilot experiments and easier to scale. On-chip multiplexing simplifies workflows while making single cell sequencing more accessible to all."
GEM-X Universal 3' Gene Expression Multiplex is compatible with Chromium Xo and X instruments. GEM-X Universal 5' Gene Expression Multiplex is exclusively available on Chromium X instruments. All GEM-X Universal Multiplex assays are now available for pre-order and are expected to begin shipping later this quarter.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, scale, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-delivers-single-cell-for-a-single-cent-with-new-chromium-launches-302276878.html
SOURCE 10x Genomics, Inc.
FAQ
What are the key features of 10x Genomics' new GEM-X Flex product?
How does the GEM-X Universal Multiplex product improve single cell analysis?
What is the main goal of 10x Genomics' new product launches in 2024?
When will the new 10x Genomics products (TXG) be available to customers?
